Developing novel anti-cancer agens by high throughput chemical screens for small molcules that modulate the pro-survival

通过高通量化学筛选调节促生存的小分子来开发新型抗癌药物

• 批准号: nhmrc : 305536
• 负责人: A/Pr Ian Street
• 金额: $ 8.34万
• 依托单位: The Walter and Eliza Hall Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Development Grants
• 财政年份: 2004
• 资助国家: 澳大利亚
• 起止时间: 2004-01-01 至 2004-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/developing-novel-anti-pro-survival/78098
• 关键词: Developing; novel; anti; cancer; agens

Cancer is the second commonest cause of deaths in our community. Unfortunately, treatment often fails or causes unwanted side effects. This proposal seeks to discover and develop a novel class of anti-cancer drugs that act by directly activating programmed cell death (apoptosis). The Bcl-2 proteins are key regulators of cell death and by exploiting knowledge about these prime targets for cancer therapy, we aim to discover drugs that are potentially of considerable medical and commercial value.

癌症是我们社区第二大常见的死亡原因。不幸的是，治疗经常失败或导致不必要的副作用。该提案旨在发现和开发一类通过直接激活程序性细胞死亡（凋亡）发挥作用的新型抗癌药物。Bcl-2蛋白是细胞死亡的关键调节因子，通过利用有关这些癌症治疗主要靶点的知识，我们的目标是发现潜在的具有相当大的医疗和商业价值的药物。